Table 2.
Control | SAH | SAH + SB386023-b after 0 hours |
SAH + SB386023-b after 6 hours |
|
---|---|---|---|---|
frontal cortex | 141 ± 16a | 75 ± 20a, b | 132 ± 17b | 135 ± 19b |
parietal cortex | 169 ± 30a | 68 ± 14a, b | 141 ± 28b | 132 ± 30b |
occiptal cortex | 137 ± 17a | 67 ± 21a, b | 141 ± 20b | 155 ± 21b |
caudate putamen | 131 ± 17a | 71 ± 20a, b | 129 ± 16b | 142 ± 18b |
Septum | 115 ± 24a | 60 ± 20a, b | 104 ± 18 | 128 ± 20b |
hippocampus | 147 ± 25a | 52 ± 11a, b | 88 ± 13b | 85 ± 20b |
Thalamus | 120 ± 16a | 64 ± 16a, b | 124 ± 17b | 136 ± 15b |
Hypothalamus | 107 ± 20 | 55 ± 16b | 95 ± 9 | 127 ± 15b |
Corpus callosum | 80 ± 19 | 41 ± 18 | 57 ± 14 | 87 ± 14 |
sensorimotor cortex | 164 ± 27 | 74 ± 20 | 134 ± 15b | 140 ± 17b |
superiour colliculus | 197 ± 27a | 70 ± 20a, b | 121 ± 12b | 130 ± 17b |
inferior colliculus | 122 ± 5a | 71 ± 19a, b | 134 ± 21b | 67 ± 21b |
cerebellar cortex | 127 ± 25a | 53 ± 14a, b | 116 ± 25b | 135 ± 27b |
dentate nucleus | 133 ± 20a | 53 ± 14a, b | 127 ± 17b | 114 ± 20b |
facial nucleus | 170 ± 31a | 70 ± 21a, b | 156 ± 32b | 131 ± 30b |
cochlear nucleus | 150 ± 30a | 54 ± 15a, b | 150 ± 21b | 119 ± 25b |
vestibular nucleus | 153 ± 18a | 75 ± 23a, b | 167 ± 22b | 130 ± 20b |
trigeminal nucleus | 154 ± 22a | 65 ± 19a, b | 149 ± 22b | 124 ± 23b |
Values are expressed in ml/min/100 g and given as mean ± s.e.m. a = significant difference between SAH and control groups, b = significant difference between SAH and SAH treated with SB386023-b 0 hr and 6 hr post SAH.